AI for pharma and pharmaceutical companies: from CMC dossier to pharmacovigilance
Pharma, biotech and MedTech organisations operate in an environment where any automated system may be GxP-relevant. From clinical research to batch release, and from eCTD submissions to signal detection in adverse events, AI offers significant time savings, but only if the solution complies with 21 CFR Part 11, EU GMP Annex 11, GAMP 5 and the latest EMA guidelines on artificial intelligence. We build AI solutions that your QA department can validate, without compromising on data quality, audit trails or patient safety.
Discuss your pharma AI case View applicationsWhy pharma needs a dedicated AI approach
A general LLM implementation that works well in retail or marketing will not meet the requirements of pharma. As soon as an AI system affects product quality, batch release, clinical decisions or pharmacovigilance, it falls under GxP and must be validated in accordance with GAMP 5. The architectural choices you make in this context are fundamentally different from those in non-regulated industries.
A biotech start-up running a Phase II clinical study collects data from electronic CRFs, ePRO apps, lab LIMS and wearables. A large pharmaceutical company navigates eCTD modules, MedDRA coding, ATC classifications and MES events on production lines that emit sensor data every second. In both cases, AI promises acceleration: less manual review of CMC documents, faster patient recruitment and earlier detection of deviations in the cold chain. However, every model that goes into production must be auditable, not only for your own QA but also for the FDA, EMA, MHRA or a GCP inspector who may want to reconstruct your decision-making process years later.
For this reason, we always approach AI within pharmaceutical environments from two questions: does this deliver a measurable benefit in time, cost or patient safety, and can the system be validated without the validation overhead cancelling out that benefit? Sometimes this means a classifier running within a validated document management system. Sometimes it means an LLM-based assistant with strict guardrails outside the GxP perimeter. And sometimes, which is a legitimate answer, it means no AI application at all, because a rule-based solution is sufficient and easier to validate.
Core areas where AI adds value in pharma
From regulatory affairs to manufacturing, AI touches nearly every link in the pharmaceutical value chain. Each area carries different validation requirements and different risk classifications.
Document AI for CMC, IND and NDA
The CMC sections of an eCTD submission quickly run to thousands of pages. An AI pipeline extracts specifications, batch data, stability data and cross-references from Module 3, compares them with previous submissions and flags inconsistencies. Regulatory writers retain editorial control; the tool eliminates the searching and checking work. Suitable for both innovator files and generic ANDA procedures.
Pharmacovigilance and signal detection
Adverse event reports come in via E2B(R3), call centres, social media and the literature. NLP models normalise free text to MedDRA Preferred Terms, link them to ATC codes and flag statistical disproportionality. Your pharmacovigilance team therefore no longer works on isolated cases but on structured signals, with a complete audit trail to support PSUR and RMP updates.
Cold-chain and GDP optimisation
The distribution of temperature-sensitive products falls under GDP. AI models analyse IoT sensor data from cold chains, predict temperature excursions before they occur, and optimise routes and buffer locations. The result: fewer excursions, fewer discarded batches and fewer deviation reports. Integrates with existing WMS and TMS systems and their validation status.
Clinical trial recruitment and retention
A phase III study more often stumbles over recruitment than over the science. AI models analyse EHR data (within legal frameworks) and public registries to identify suitable patients at trial sites, predict no-shows and flag retention risks. EU CTR-compliant, with explicit consent flows and pseudonymisation in line with GDPR and HIPAA.
Predictive QC in manufacturing
MES and SCADA data, in-line PAT sensors and LIMS results together provide enough signal to predict batch deviations before final testing takes place. Models run alongside your release criteria, not instead of them. Implementation accounts for 21 CFR Part 11 audit trails and the validation regimes of Werum PAS-X, Aspen or comparable ERP-Pharma platforms.
Regulatory affairs automation
Health authority queries, change control, labelling updates and periodic safety updates rely heavily on document work. AI supports regulatory teams with draft generation, cross-checks between SmPC versions and automatic tracking of regulatory changes at the EMA, FDA and national authorities. Output always needs to be reviewed by a regulatory affairs manager before submission.
How Appfront builds AI within pharma organisations
We do not supply an off-the-shelf pharma platform. The pharma sector is too diverse for that: a MedTech start-up with a single SaMD product has different needs from an established manufacturer with ten production sites and hundreds of marketed products. Our role is that of a build partner: from data assessment to validation support to production implementation within your existing IT and QA landscape.
From day one we work alongside your QA, validation and regulatory functions. A use case that is GxP-relevant immediately receives a Computer System Validation strategy in line with GAMP 5: risk classification, URS, FS, configuration baseline, IQ/OQ/PQ protocols and ongoing periodic reviews. Not GxP-relevant? Then we opt for a lighter regime, but we document explicitly why, so that any later reclassification comes as no surprise.
Our approach is iterative. We start with a proof of concept on a defined, pseudonymised dataset: for example a document classifier on a subset of your CMC archive, or a signal detection model on historical E2B data. Only once the PoC demonstrates that it works and we can see a validation route do we move to production. That saves you a multi-year validation project without end-user acceptance.
From use case selection to validated production
Our approach to AI in pharma follows four phases. Each phase ends with a tangible deliverable that your QA, regulatory and business stakeholders can review together, with no big-bang implementation and no absence of interim results.
GxP assessment
Together we determine whether the use case is GxP-relevant, which GAMP 5 category applies and which regulations are affected: 21 CFR Part 11, Annex 11, EU CTR, the EMA AI Reflection Paper or the AI Act for MedTech. Output: an agreed scope and risk baseline.
Proof of concept
Within a few weeks, we build a working prototype on pseudonymised data: a classifier on CMC documents, a signal detection pipeline on historical adverse events, or a predictive model on MES data. Concrete, testable and without validation overhead.
Validation and integration
If the PoC outcome is positive, we draft the URS, FS and validation protocols in accordance with GAMP 5. Integration with DMS, LIMS, MES, ERP-Pharma or safety databases takes place through validated interfaces with audit trails compliant with 21 CFR Part 11 and Annex 11.
Periodic review
AI models do not perform indefinitely. We provide monitoring for model drift, periodic retraining and the associated change controls, including documentation for inspections by the FDA, EMA or national regulators such as the IGJ.
Technology we use in pharma projects
Our choice of stack depends on the regulatory context. For GxP systems, we choose frameworks with deterministic behaviour, reproducible builds and strong audit trail capabilities. For document AI, we work with transformer models that we fine-tune on pharma-specific corpora, such as pharmacopoeia text, SmPCs and CMC sections, so that the model is familiar with specialist terminology like USP, Ph. Eur., dissolution profiles and API/excipient specifications.
For signal detection in pharmacovigilance, we use models that predict MedDRA codes from free text, combined with classic disproportionality methods (PRR, ROR, IC). For cold chain and manufacturing, we choose time series models that remain transparent: no black-box deep learning on production processes that inspectors could take apart without a clear answer to the "why" question.
Test your idea first: a working prototype in 1 day
With OneDayBuild, we turn your idea into something tangible in one day for €1,150, so you can see whether further development is worth the investment. Decide to go ahead with the full build? Then we credit the full cost.
Explore OneDayBuild →Compliance: GxP, CSV and the AI Act within one architecture
An AI solution that QA does not approve delivers no value. From the very first sprint, we design with validation in mind. Not as an afterthought, but as an architectural starting point.
21 CFR Part 11 and Annex 11
Audit trails, electronic records, electronic signatures and data integrity (ALCOA+) are non-negotiable. We implement append-only logging, role-based access control, secure timestamping and complete change history at record level. Documentation aligns with your existing SOPs for electronic records.
GAMP 5 and CSV
Computer System Validation in accordance with GAMP 5 is our guiding framework. We classify each component (Cat 1 to 5), draw up a differentiated validation strategy and deliver URS, FS and IQ/OQ/PQ protocols in a form that fits your QMS. For AI components, we apply the GAMP 5 second edition guidance.
EMA AI Reflection Paper and the AI Act
The EMA's reflection paper on AI in the medicinal product lifecycle and the EU AI Act (high-risk classification for MedTech and parts of pharma) partly determine the requirements for transparency, robustness, human oversight and post-market monitoring. We translate these into concrete architectural decisions and governance documents.
GDPR, HIPAA and data hosting
Patient data, clinical data and adverse event reports are special category personal data. We host in EU data centres, use pseudonymisation during training, and conclude data processing agreements with technical and organisational measures that can be verified by the Dutch Data Protection Authority, the IGJ and foreign regulators. No cross-border data flows without a well-founded legal basis.
Practical scenarios within pharmaceutical organisations
AI in pharma is not a thing of the future. The applications below are well buildable and validatable with the current state of the technology, provided the scope is right from the start.
CMC classifier on a Module 3 archive
A mid-sized pharma company wants to check consistency with earlier CMC sections for every new submission. A document classifier and NER pipeline extracts specifications, method descriptions and stability data from Module 3. Regulatory writers receive automatically generated diff reports against historical submissions, so cross-reference errors are caught at the drafting stage.
Signal detection on E2B(R3) ICSR feeds
A pharmacovigilance team processes thousands of ICSRs a month. An NLP pipeline normalises free-text narratives to MedDRA Preferred Terms and LLT codes, links them to ATC classifications and then runs disproportionality analyses. Triage decisions remain with the PV officer; the tool delivers a structured, justified shortlist, useful for PSUR and RMP updates.
Cold-chain anomaly detection
A wholesaler holding a GDP licence receives sensor data from hundreds of shipments a day. A model predicts temperature excursions based on route, vehicle, weather forecasts and each carrier's history. Operations can intervene before an excursion occurs, deviation reports decrease, and the value of rejected batches demonstrably falls.
Patient recruitment for clinical research
A biotech start-up is looking for phase II patients with a specific mutation profile. An AI pipeline searches structured EHR fields in participating hospitals and public registries, within consent boundaries and with strict pseudonymisation. Site coordinators receive a list of suitable candidates with the rationale for each criterion, in line with EU CTR and GCP.
Why Appfront for AI in pharma
Industry jargon and regulation as the starting point
We know the difference between an SmPC and an IB, between a PSUR and an RMP, and between GxP categories within GAMP 5. We translate that domain language directly into architecture, with no workshops needed to explain what an eCTD module is.
Validation as a design principle
CSV is not an afterthought but an input to the architectural design. From day one we build in audit trails, role-based access and deterministic builds, rather than bolting on QA afterwards with all the rework that entails.
From proof of concept to post-market
Many AI projects stall between prototype and production. We support the entire journey, including periodic review and model drift monitoring, so that an AI component is maintained just as well as your other GxP systems.
Frequently asked questions about AI in pharma
Thinking about deploying AI in your pharma organisation?
Discuss your use case with us. Together we will establish whether the application is GxP-relevant, which validation route fits and what a realistic PoC scope looks like.
Schedule a conversation